A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study

Suspended
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Poseltinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAjuvenate
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 Apr 2018 This trial has been discontinued in Poland.
    • 09 Mar 2018 Planned End Date changed from 1 May 2019 to 1 Mar 2019.
    • 09 Mar 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top